Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.55 |
| ▸ | ITGAL | P20701 | 20/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445347 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL31021042 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445336 | 0.86 | ITGB2 (0.58) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445338 | 0.86 | ITGB2 (0.52) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL27044025 | 0.85 | ITGB2 (0.58) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL29739237 | 0.85 | ITGB2 (0.64) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20617064 | 0.85 | ITGB2 (0.61) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL10129634 | 0.85 | ITGB2 (0.64) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13666955 | 0.84 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20618441 | 0.84 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021130168-A1 | A PHARMACEUTICAL FORMULATION | WARSZAWSKIE ZAKLADY FARMACEUTYCZNE POLFA SA (PL) | 2021-07-01 | — | — | WO | disclosed |
| EP-3842032-A1 | A PHARMACEUTICAL FORMULATION | Warszawskie Zaklady Farmaceutyczne Polfa S.A. (PL) | 2021-06-30 | — | — | EP | disclosed |
| US-10428052-B2 | Process for preparing lifitegrast and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2019-10-01 | — | — | US | disclosed |
| US-20190002445-A1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2019-01-03 | — | — | US | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002445-A1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | LIFR, FLT3, NUDT21 | ITGB2 923/4885ICAM1 3953/4885ITGAL 934/4885 |
| US-10428052-B2 | Process for preparing lifitegrast and intermediates thereof | LIFR, FLT3, NUDT21 | ITGB2 923/4885ICAM1 3953/4885ITGAL 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.